Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 421 to 435 of 1363 results for social care

  1. Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]

    Awaiting development Reference number: GID-TA11218 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]

    Awaiting development Reference number: GID-TA11458 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. DCVax-L for treating glioblastoma [ID836]

    In development Reference number: GID-TA10143 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Effective interventions for addressing child abuse and neglect in the UK:- What interventions, approaches and methodologies provided by social care and voluntary sectorservices are effective and cost effective in the UK to prevent the recurrence of child abuse and neglect, and to improve the wellbeing of children, young people and families?

    the UK:- What interventions, approaches and methodologies provided by social care and voluntary sectorservices are effective and cost...

    Research recommendation
    Published
    18 October 2018

  5. Get a HealthTech evaluated

    Our Medical Technologies Evaluation Programme (MTEP) considers technologies that could offer benefits to patients and the health and social care system over current practice.

  6. Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]

    In development Reference number: GID-TA10748 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Nirogacestat for treating desmoid tumours [ID6453]

    In development Reference number: GID-TA11559 Expected publication date:  10 June 2026

    Technology appraisal guidance
    In development

  8. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]

    In development Reference number: GID-TA11674 Expected publication date:  07 May 2026

    Technology appraisal guidance
    In development

  9. Depression in adults with a chronic physical health problem: recognition and management (CG91)

    This guideline covers identifying, treating and managing depression in people aged 18 and over who also have a chronic physical health problem such as cancer, heart disease or diabetes. It aims to improve the care of people with a long-term physical health problem, which can cause or exacerbate depression. This has the potential to increase their quality of life and life expectancy.

    Clinical guideline
    Published
    28 October 2009
    View recommendations

    Sections for CG91

  10. How to apply to join a committee

    and social care services. By joining, you'll have the opportunity to make a difference in the lives of others by developing health and...

  11. How to apply to join a committee

    and social care services. By joining, you'll have the opportunity to make a difference in the lives of others by developing health and...

  12. Peripheral arterial disease (QS52)

    This quality standard covers diagnosing and managing lower limb peripheral arterial disease in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    21 January 2014
    View quality statements

    Sections for QS52

  13. Guidance, NICE advice and quality standards in development

    View a complete list of all our guidance, NICE advice and quality standards currently in development

  14. OpenAthens registration help

    Help with registering for your NHS OpenAthens account.

  15. Promoting health and preventing premature mortality in black, Asian and other minority ethnic groups (QS167)

    This quality standard covers promoting health and preventing premature mortality among black, Asian and other minority ethnic groups. It is relevant to all age groups and all settings.

    Quality standard
    Published
    11 May 2018
    View quality statements

    Sections for QS167